Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 7/20 | 0.48 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | PYGM | P11217 | 1/20 | 0.44 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.43 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3993018 | 0.94 | GPR132 (0.59) | GPR132PTPN1CMKLR2CMKLR1 | |
| SCHEMBL5926744 | 0.93 | SERPINE1 (0.56) | SERPINE1PTPN1 | |
| SCHEMBL5926619 | 0.90 | ITGA4 (0.47) | SERPINE1 | |
| SCHEMBL5926197 | 0.88 | SERPINE1 (0.49) | SERPINE1PTPN1 | |
| SCHEMBL5926815 | 0.88 | GPR34 (0.55) | GPR132SERPINE1PTPN1 | |
| SCHEMBL5926633 | 0.87 | SERPINE1 (0.45) | GPR132SERPINE1F10PTPN1 | |
| SCHEMBL5926977 | 0.87 | FFAR1 (0.45) | — | |
| SCHEMBL5927230 | 0.87 | GRN (0.47) | GPR132SERPINE1F10 | |
| SCHEMBL5927527 | 0.86 | SERPINE1 (0.52) | SERPINE1PTPN1 | |
| SCHEMBL5927430 | 0.86 | GPR34 (0.47) | SERPINE1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014533-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | GPR132 3507/4885SERPINE1 27/4885F10 9/4885 |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | GPR132 2429/4885SERPINE1 56/4885F10 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.